@article{oai:repo.qst.go.jp:00044065,
 author = {Watanabe, Naoyuki and Oriuchi, Noboru and Endou, Keigo and Inoue, Tomio and Tanada, Shuji and Murata, Hajime and Sasaki, Yasuhito and 渡辺 直行 and 遠藤 啓吾 and 井上 登美夫 and 棚田 修二 and 村田 啓 and 佐々木 康人},
 issue = {7},
 journal = {Nuclear Medicine and Biology},
 month = {},
 note = {The aim of this study was to investigate the possibility of yttrium-90-labeled human macroaggregated albumin (90Y-MAA)as an internal radiotherapeutic agent for whole-lung irradiation in combination with diethylenetriamine pentaacetic acid (DTPA).  The influence of trisodium calcium DTPA (CaNa3DTPA) on the radioactivity of 90Y-MAA in serum wa investigated in vitro.  The effect of CaNa3DTPA on the biodistribution of radioactivity in normal mice intraveneously injected with 90Y-MAA was examined. CaNa3DTPA could deprive in vitro radioactivity of 90Y-MAA in 48-h incubation. Most of the radioactivity (>90% injected dose per lung) was observed at murine lung after injection of 90Y-MAA.  Pulmonary radioactivity was cleared within 72 h postinjection, whereas the radioacivities in the bone, liver, kidneys, and spleen increased with a peak at 48 h. CaNa3DTPA-treatment reduced the in vivo radioactivities in bone, liver, and kidneys without influence on the radioactivity of lung.  In conclusion, combined use of CaNa3DTPA enables 90Y-MAA to be used as a radiopharmaceutical for internal irradiation against whole lung.},
 pages = {847--851},
 title = {Yttrium-90-Labeled Human Macroaggregated Albumin for Internal Radiotherapy: Combined Use with DTPA},
 volume = {26},
 year = {1999}
}